title: A randomized controlled trial to evaluate short-term treatment with eosin vs. topical steroids in psoriasis.
abstract: BACKGROUND
  The therapeutic effects of some histological staining agents on psoriasis have been reported in the past. One of these agents is eosin, which is still currently used in routine treatment, although it has never been formally tested in a randomized controlled trial. Aim. To compare treatment with eosin in patients with moderate to severe psoriasis vs. short-course topical steroid, a well-defined, evidence-based treatment.
  
  
  METHODS
  A randomized trial was designed and conducted. The Skindex-29 and General Health Questionnaire (GHQ)-12 questionnaires, and Psoriasis Activity and Disease Index (PASI) were used before treatment in 43 patients. Five days after treatment, PASI was measured again.
  
  
  RESULTS
  Five days after treatment, a significant mean reduction of PASI was observed in both groups: 6.8 (95% CI 5.5-8) for eosin, and 5.2 (3.2-7.1) for steroids. The difference between the two groups was not significant (P = 0.161).
  
  
  CONCLUSIONS
  Eosin has a short-term effect similar to topical steroids. The low cost of eosin treatment and its limited collateral effects suggest that eosin could be an effective steroid-sparing agent in the initial phase of psoriasis treatment.
authors.affiliation: Health Services Research, IDI IRCCS, Rome, Italy. ste.tab@idi.it
authors.forename: S
authors.initials: S
authors.lastname: Tabolli
authors.forename: L
authors.initials: L
authors.lastname: Alessandroni
authors.forename: B
authors.initials: B
authors.lastname: Didona
authors.forename: C
authors.initials: C
authors.lastname: Di Pietro
authors.forename: P
authors.initials: P
authors.lastname: Gisondi
authors.forename: L
authors.initials: L
authors.lastname: Rota
authors.forename: F
authors.initials: F
authors.lastname: Sampogna
authors.forename: D
authors.initials: D
authors.lastname: Abeni
mesh_terms: D000328:Adult; D001623:Betamethasone / Q000031:analogs & derivatives / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004801:Eosine Yellowish-(YS) / Q000627:therapeutic use*; D005260:Female; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007641:Keratolytic Agents / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D017060:Patient Satisfaction; D011565:Psoriasis / Q000188:drug therapy*; D012720:Severity of Illness Index; D016896:Treatment Outcome
chemical_list: D005938:Glucocorticoids; D007641:Keratolytic Agents; C085708:betamethasone 21-valerate; D001623:Betamethasone; D004801:Eosine Yellowish-(YS)